Qiagen launches QIAstat-Dx Rise
November 2025—Qiagen launched QIAstat Dx Rise, an FDA-cleared automated syndromic testing system for hospitals and laboratories.
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Ifinatamab deruxtecan gets breakthrough therapy designation
November 2025—The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for treating extensive-stage small cell lung cancer after platinum-based chemotherapy.
Guardant, PathGroup partner to expand access to Shield test
November 2025—Guardant Health and PathGroup are partnering to expand access to Guardant’s FDA-approved Shield blood test for colorectal cancer screening.
Data presented at ACEP25 show the utility of MeMed BV
November 2025—Presentations at the American College of Emergency Physicians Scientific Assembly 2025 highlighted MeMed BV’s effectiveness in distinguishing between bacterial and viral infections.
Quickvue Influenza + SARS test available for professional use
November 2025—QuidelOrtho’s Quickvue Influenza + SARS test, a CLIA-waived immunoassay, is now available for professional use.
Quest launches advanced PGx test service
November 2025—Quest Diagnostics launched a pharmacogenomic laboratory test service to help providers understand a patient’s genetic response to drug therapies.
Abbott gets expanded approval for HPV assay
November 2025—FDA approves Abbott’s Alinity m HR HPV assay for self-collected vaginal samples in clinical settings.
CytoCell KMT2A FISH probe kit granted de novo classification
November 2025—FDA granted de novo classification for OGT’s CytoCell KMT2A Breakapart FISH Probe Kit PDx as a companion diagnostic for Syndax’s menin inhibitor, Revuforj.
Tosoh gets clearance for next-gen GR01 HbA1c analyzer
November 2025—Tosoh Bioscience received FDA clearance for its HLC 723-GR01 analyzer, which uses proprietary technology to deliver A1c results in 50 seconds and detect common hemoglobin variants.
Molecular Designs submits respiratory panel for 510(k) clearance
November 2025—Molecular Designs submitted a 510(k) premarket notification to the FDA for its SimplicityDx Respiratory panel, designed to detect SARS-CoV-2, influenza A, influenza B, and RSV.